NCT06117878View on ClinicalTrials.gov

Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2024

Conditions
OsteosarcomaSoft Tissue Sarcoma
Interventions
DRUG

NK510

NK510 will be administered through intravenous infusion.once a week，for a total of six times.

DRUG

NK510

NK510 will be administered through intravenous infusion.Twice infusions on week 1,week 3,week 5 respectively.

Trial Locations (1)

Unknown

RECRUITING

Shanghai General Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

lead

Base Therapeutics (Shanghai) Co., Ltd.

INDUSTRY